Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but remains well below its 52-week high ...

U.S. stock indexes slipped and gave back some of their rallies from the day before, while oil prices got back to rising. The S&P 500 fell 0.4% Tuesday after yo-yoing through the day. The Dow ...

Protalix BioTherapeutics, Inc. is rated a Buy due to robust FY26 revenue guidance of $78–83 million. Learn more about PLX stock here.

Shares of Valneva VALN tanked 37% on Monday after the company reported top-line results from the phase III VALOR study, which ...

Pfizer (NYSE: PFE) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over ...

Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over 70% efficacy. The trial did not meet its primary endpoint, mainly due to lower than expected Lyme ...

Despite the study missing its primary endpoint, Pfizer will continue with the regulatory submission of the vaccine.

The stock market just broke below its 200-day Simple Moving Average, and fear is accelerating. The popular S&P 500 ETF, the SPDR S&P 500 ETF Trust (NYSEARCA: SPY), not only sliced through that key ...

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.

Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until the stock exceeds $32. A closing-price condition could result in payment ...

Damora Therapeutics Inc (NASDAQ:DMRA) shares jumped 15.5% Monday following the announcement of Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Jarrett brings ...